(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Bio Techne's revenue in 2025 is $1,219,635,000.On average, 19 Wall Street analysts forecast TECH's revenue for 2026 to be $196,770,227,555, with the lowest TECH revenue forecast at $187,126,153,161, and the highest TECH revenue forecast at $205,169,905,253. On average, 18 Wall Street analysts forecast TECH's revenue for 2027 to be $211,858,537,494, with the lowest TECH revenue forecast at $196,459,128,381, and the highest TECH revenue forecast at $232,702,182,152.
In 2028, TECH is forecast to generate $234,102,128,435 in revenue, with the lowest revenue forecast at $212,169,636,668 and the highest revenue forecast at $265,523,145,009.